Envision the possibility of fewer idiopathic gastroparesis symptoms

Idiopathic Gastroparesis

The Envision GI study is a clinical research study for people who have been diagnosed with idiopathic gastroparesis. The main purpose of this study is to find out how well the study medication (CIN-102, deudomperidone) improves the symptoms associated with idiopathic gastroparesis.

Study information:

  • Condition: Idiopathic Gastroparesis

  • Location: Las Vegas, Nevada

  • Duration: Up to 18 weeks

  • Participation: Up to 8 visits

  • Compensation: Up to $1375

Eligibility:

  • Age 18 or older

  • Diagnosis of idiopathic gastroparesis

  • Gastrointestinal symptoms such as:

    • Nausea or vomiting after eating

    • Feeling too full after eating

    • Bloating

    • Throat or stomach pain

  • Other study requirements apply.

Participants may receive:

  • Compensation up to $1375

  • Study support and monitoring by a healthcare team

  • Diagnostic tests and procedures at no-cost

  • Access to a new possible therapy for people with idiopathic gastroparesis

  • Some participants will receive placebo, which will have no effect on their condition

Get started today.

You are not committed to participate in a study by completing this form. Participation is voluntary, and you may leave at any time if you change your mind.

What is idiopathic gastroparesis?

Common terms for gastroparesis are:

  • Delayed gastric emptying

  • Slow stomach emptying

  • Gastric dysmotility

  • Gastric stasis

  • Lazy stomach

Idiopathic gastroparesis is a condition that prevents the stomach from emptying normally. It occurs without a known primary cause. Common symptoms include stomach discomfort, nausea, vomiting, upper abdominal pain, feeling full after consuming only a small amount of food, or feeling of persistent fullness after eating. These symptoms can be hard to manage and lead to other complications.

Although a medication (domperidone) to treat gastroparesis is used in some countries, it is not approved in the United States because it can have serious side effects. It can be used under a special agreement between a physician and the Food and Drug Administration. The study medication being investigated (deudomperidone) is designed to have similar benefits with fewer side effects. What we learn from the Envision GI study may help researchers learn more about a potential new idiopathic gastroparesis treatment option.

Information provided by: https://www.gastroparesisstudy.com/